POS1247 CLINICAL FEATURES AND OUTCOMES OF COVID-19 IN PATIENTS WITH IGG4-RELATED DISEASE. A COLLABORATIVE EUROPEAN MULTI-CENTRE STUDY

Background:Coronavirus disease 2019 (COVID-19) is a pandemic-spread systemic infectious disease with prominent respiratory manifestations and significant associated morbidity and mortality. Elderly people are most significantly affected with mortality ranging from 2.4% (age 60-69) to 19.6% (age>80) in European Countries. The prevalence of COVID-19 and of its complications in patients with immune-mediated disorders, remains unclear. The frequency and impact of COVID-19 on patients with IgG4-related diease (IgG4-RD), many of whom are on concurrent immunosuppression has not been addressed.Objectives:To assess the epidemiological and clinical relevance of COVID-19 in patients with IgG4-RD.Methods:This is a multi-centre retrospective observational study of IgG4-RD patients from France, Italy, Spain and the United Kingdom. Demographics, comorbidities, IgG4-RD features, current and past treatment along with COVID-19-suggestive symptoms and COVID-19 diagnoses from February 2020 to January 2021 were recorded by means of direct or phone interviews. Patients with reverse-transcriptase polymerase chain reaction-confirmed (cCOVID) or presumed COVID-19 based on clinical, serological or imaging features (pCOVID) were pooled for analysis (totCOVID) and compared to patients who were not diagnosed with COVID-19. Inter-group comparison of categorical and quantitative variables were performed by using the chi-square test with Fisher's correction and the Mann-Whitney's test respectively. Data are expressed as median (interquartile range) unless otherwise specified.Results:A total of 305 patients [71% males, median age 64 (54-74) years] were studied. Pancreato-biliary disease was the most frequently observed IgG4-RD phenotype (39%). Fifty-one percent of patients were taking corticosteroids at time of interview and 30% were on biological or conventional immunosuppressants. Thirty-two totCOVID cases (23 cCOVID, nine pCOVID) were identified: 11/32 were hospitalised, two needed intensive care and four (13%; 3/4 aged >80 years) died. Having one or more infected family members was a risk factor for COVID-19 in patients with IgG4-RD (OR=19.9; p20mg) or rituximab administration.Conclusion:The prevalence and course of COVID-19 in IgG4-RD patients are similar to those of the general population of the same age, with no evident impact of disease- or treatment-related factors to the basal infectious risk. Effective public health countermeasures might be beneficial for patients with IgG4RD.References:[1]European Centre for Disease Prevention and Control (ECDC): https://covid19-surveillance-report.ecdc.europa.eu/[2]Yang H, Ann Rheum Dis, 2021Disclosure of Interests:Giuseppe Alvise Ramirez: None declared, Marco Lanzillotta: None declared, Mikael Ebbo: None declared, Andreu Fernandez-Codina Consultant of: consulting fees from Atheneum Consulting, Gaia Mancuso: None declared, Fernando Martínez-Valle: None declared, Olimpia Orozco-Galvez: None declared, Nicolas Schleinitz: None declared, Lorenzo Dagna Consultant of: Abbvie, Amgen, Biogen, BristolMyers Squibb, Celltrion, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI, Grant/research support from: The Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) received unresctricted research/educational grants from Abbvie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline,Janssen, Merk Sharp & Dohme, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi Genzyme, and SOBI, Emma L. Culver: None declared, Emanuel Della Torre: None declare

Agonistes du récepteur de la thrombopoïétine et purpura thrombopénique immunologique de l'adulte : où en sommes-nous 10 ans après ?

International audienc

An evaluation of sub-acute toxicity of Chrozophora senegalenses on albino rats

Sub-acute toxic effects of the plant Chrozophora senegalenses which has been claimed by the Hausa/Fulani traditional healers to have some medicinal properties like anti-diarrhea, syphilis, typhoid fever and conjunctivitis has been analyzed in this study. The experimental albino rats were administered a graded doses of the aqueous extract orally for 28 days after which the blood and serum samples were collected for hematology and blood chemistry. No significant difference (p>0.05) was observed with regards to all the parameters investigated except for urea and conjugated bilirubin at the highest dose of 1,500mg/kg. It can therefore be concluded that the extract of this plant at a dose less than 1,500mg/kg within the period of 28days is safe in Albino rats.Keywords- Albino rats, Chrozophora senegalenses, Medicinal properties, Sub-acute toxicit

Anticorps anti-cytokines : quel impact clinique en pathologie humaine ?

International audienceAnti-cytokine antibodies (ACA) are an emerging cause of acquired immunodeficiency, especially in previously healthy adults. The most frequently reported are anti-IFN-γ responsible for disseminated non-tuberculous mycobacteria infections, and anti-GM-CSF mainly in mycobacteria, cryptococcosis and nocardiosis infections. The presence of anti-IFN-α in severe COVID-19 infections has recently been described. The search for and detection of these ACAs in an unusual infection situation makes it possible to set up specific therapies in addition to the anti-infective treatment. ACAs are also frequent in various autoimmune pathologies where, in addition to being indicators of the breakdown of immune tolerance, they can modulate the activity of the disease according to their cytokine target. In this review of the literature, we will focus on the epidemiology and the clinical impact of these ACAs in healthy subjects and in infectious or dysimmune diseases.Les anticorps anti-cytokines (ACA) sont une cause émergente d’immunodéficience acquise, notamment chez le sujet adulte auparavant en bonne santé. Les plus fréquemment rapportés sont les anti-IFN-γ responsables d’infections à mycobactéries non tuberculeuses disséminées, et les anti-GM-CSF principalement dans les infections à mycobactéries, cryptococcoses et nocardioses, ont récemment été décrits la présence d’anti-IFN-α dans les infections sévères à COVID-19. La recherche et la détection de ces ACA en situation d’infection inhabituelle permettent de mettre en place des thérapeutiques spécifiques en adjonction au traitement anti-infectieux. Les ACA sont également fréquents dans différentes pathologies auto-immunes où, en plus d’être des témoins de la rupture de tolérance immunitaire, ils peuvent moduler l’activité de la maladie selon leur cible cytokinique. Dans cette revue de la littérature nous mettrons l’accent sur l’épidémiologie et l’impact clinique de ces ACA chez le sujet sain et en situation pathologique infectieuse ou dysimmunitaire

Anticorps anti-cytokines : quel impact clinique en pathologie humaine ?

International audienceAnti-cytokine antibodies (ACA) are an emerging cause of acquired immunodeficiency, especially in previously healthy adults. The most frequently reported are anti-IFN-γ responsible for disseminated non-tuberculous mycobacteria infections, and anti-GM-CSF mainly in mycobacteria, cryptococcosis and nocardiosis infections. The presence of anti-IFN-α in severe COVID-19 infections has recently been described. The search for and detection of these ACAs in an unusual infection situation makes it possible to set up specific therapies in addition to the anti-infective treatment. ACAs are also frequent in various autoimmune pathologies where, in addition to being indicators of the breakdown of immune tolerance, they can modulate the activity of the disease according to their cytokine target. In this review of the literature, we will focus on the epidemiology and the clinical impact of these ACAs in healthy subjects and in infectious or dysimmune diseases.Les anticorps anti-cytokines (ACA) sont une cause émergente d’immunodéficience acquise, notamment chez le sujet adulte auparavant en bonne santé. Les plus fréquemment rapportés sont les anti-IFN-γ responsables d’infections à mycobactéries non tuberculeuses disséminées, et les anti-GM-CSF principalement dans les infections à mycobactéries, cryptococcoses et nocardioses, ont récemment été décrits la présence d’anti-IFN-α dans les infections sévères à COVID-19. La recherche et la détection de ces ACA en situation d’infection inhabituelle permettent de mettre en place des thérapeutiques spécifiques en adjonction au traitement anti-infectieux. Les ACA sont également fréquents dans différentes pathologies auto-immunes où, en plus d’être des témoins de la rupture de tolérance immunitaire, ils peuvent moduler l’activité de la maladie selon leur cible cytokinique. Dans cette revue de la littérature nous mettrons l’accent sur l’épidémiologie et l’impact clinique de ces ACA chez le sujet sain et en situation pathologique infectieuse ou dysimmunitaire